HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.

AbstractBACKGROUND AND PURPOSE:
Thrombosis of cerebral veins and sinus (cerebral venous thrombosis) is a rare stroke pathogenesis. Pharmaceutical treatment is restricted to heparin and oral anticoagulation with vitamin K antagonists (VKAs).
METHODS:
Between January 2012 and December 2013, we recorded data from our patients with cerebral venous thrombosis. The modified Rankin scale was used to assess clinical severity; excellent outcome was defined as modified Rankin scale 0 to 1. Recanalization was assessed on follow-up MR angiography. Patients were then divided into 2 treatment groups: phenprocoumon (VKA) and a novel factor Xa inhibitor. Clinical and radiological baseline data, outcome, recanalization status, and complications were retrospectively compared.
RESULTS:
Sixteen patients were included, and 7 were treated with rivaroxaban. Overall outcome was excellent in 93.8%, and all patients showed at least partial recanalization. No statistical significant differences were found between the groups, except the use of heparin before start of oral anticoagulation (P=0.03). One patient in the VKA and 2 patients in the factor Xa inhibitor group had minor bleeding (P=0.55) within the median (range) follow-up of 8 months (5-26).
CONCLUSIONS:
Factor Xa inhibitor showed a similar clinical benefit as VKA in the treatment of cerebral venous thrombosis. Further systematic prospective evaluation is warranted.
AuthorsChristina Geisbüsch, Daniel Richter, Christian Herweh, Peter A Ringleb, Simon Nagel
JournalStroke (Stroke) Vol. 45 Issue 8 Pg. 2469-71 (Aug 2014) ISSN: 1524-4628 [Electronic] United States
PMID25070963 (Publication Type: Journal Article)
Copyright© 2014 American Heart Association, Inc.
Chemical References
  • Anticoagulants
  • Factor Xa Inhibitors
  • Morpholines
  • Thiophenes
  • Rivaroxaban
  • Phenprocoumon
Topics
  • Adolescent
  • Adult
  • Aged
  • Anticoagulants (therapeutic use)
  • Factor Xa Inhibitors
  • Female
  • Humans
  • Male
  • Middle Aged
  • Morpholines (therapeutic use)
  • Phenprocoumon (therapeutic use)
  • Rivaroxaban
  • Sinus Thrombosis, Intracranial (drug therapy)
  • Thiophenes (therapeutic use)
  • Treatment Outcome
  • Venous Thrombosis (drug therapy)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: